184 related articles for article (PubMed ID: 25432695)
1. Reevaluation of glypican-3 as a prognostic marker in HCC using X-tile software.
Pan C; Wang X; Chen W; Tao C; Xu X; Jin L; Chen Y; Zhu L; Zhou L; Pan Z
Med Oncol; 2015 Jan; 32(1):359. PubMed ID: 25432695
[TBL] [Abstract][Full Text] [Related]
2. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.
Feng J; Zhu R; Chang C; Yu L; Cao F; Zhu G; Chen F; Xia H; Lv F; Zhang S; Sun L
PLoS One; 2016; 11(3):e0151501. PubMed ID: 26977595
[TBL] [Abstract][Full Text] [Related]
3. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.
Fu SJ; Qi CY; Xiao WK; Li SQ; Peng BG; Liang LJ
Surgery; 2013 Sep; 154(3):536-44. PubMed ID: 23601901
[TBL] [Abstract][Full Text] [Related]
4. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients.
Jeon Y; Kim H; Jang ES; Hong S; Kim JW; Yoon YS; Cho JY; Han HS; Jeong SH
APMIS; 2016 Mar; 124(3):208-15. PubMed ID: 26764243
[TBL] [Abstract][Full Text] [Related]
5. Decreased Expression of ZWINT is Associated With Poor Prognosis in Patients With HCC After Surgery.
Yang XY; Wu B; Ma SL; Yin L; Wu MC; Li AJ
Technol Cancer Res Treat; 2018 Jan; 17():1533033818794190. PubMed ID: 30198401
[TBL] [Abstract][Full Text] [Related]
6. Low expression of B-cell-associated protein 31 in human primary hepatocellular carcinoma correlates with poor prognosis.
Tan N; Liu Q; Liu X; Gong Z; Zeng Y; Pan G; Xu Q; He S
Histopathology; 2016 Jan; 68(2):221-9. PubMed ID: 25980696
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma.
Ohno A; Yorita K; Haruyama Y; Kondo K; Kato A; Ohtomo T; Kawaguchi M; Marutuska K; Chijiiwa K; Kataoka H
Liver Int; 2014 Jul; 34(6):942-52. PubMed ID: 24433439
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
Shirakawa H; Suzuki H; Shimomura M; Kojima M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Cancer Sci; 2009 Aug; 100(8):1403-7. PubMed ID: 19496787
[TBL] [Abstract][Full Text] [Related]
10. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
11. Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers.
Liu X; Wang SK; Zhang K; Zhang H; Pan Q; Liu Z; Pan H; Xue L; Yen Y; Chu PG
Carcinogenesis; 2015 Feb; 36(2):232-42. PubMed ID: 25542894
[TBL] [Abstract][Full Text] [Related]
12. Low expression of DCXR protein indicates a poor prognosis for hepatocellular carcinoma patients.
Hang X; Wu Z; Chu K; Yu G; Peng H; Xin H; Miao X; Wang J; Xu W
Tumour Biol; 2016 Nov; 37(11):15079-15085. PubMed ID: 27658779
[TBL] [Abstract][Full Text] [Related]
13. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin.
Yu MC; Lee YS; Lin SE; Wu HY; Chen TC; Lee WC; Chen MF; Tsai CN
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S455-63. PubMed ID: 21822558
[TBL] [Abstract][Full Text] [Related]
14. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
15. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma.
Kaseb AO; Hassan M; Lacin S; Abdel-Wahab R; Amin HM; Shalaby A; Wolff RA; Yao J; Rashid A; Vennapusa B; Feng J; Ohtomo T
Oncotarget; 2016 Oct; 7(43):69916-69926. PubMed ID: 27655712
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation.
Wang YL; Zhu ZJ; Teng DH; Yao Z; Gao W; Shen ZY
World J Gastroenterol; 2012 May; 18(19):2408-14. PubMed ID: 22654434
[TBL] [Abstract][Full Text] [Related]
17. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma.
Ofuji K; Saito K; Suzuki S; Shimomura M; Shirakawa H; Nobuoka D; Sawada Y; Yoshimura M; Tsuchiya N; Takahashi M; Yoshikawa T; Tada Y; Konishi M; Takahashi S; Gotohda N; Nakamoto Y; Nakatsura T
Oncotarget; 2017 Jun; 8(23):37835-37844. PubMed ID: 28035063
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis.
Zhang J; Zhang M; Ma H; Song X; He L; Ye X; Li X
Medicine (Baltimore); 2018 Jun; 97(24):e11130. PubMed ID: 29901640
[TBL] [Abstract][Full Text] [Related]
19. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
Capurro M; Wanless IR; Sherman M; Deboer G; Shi W; Miyoshi E; Filmus J
Gastroenterology; 2003 Jul; 125(1):89-97. PubMed ID: 12851874
[TBL] [Abstract][Full Text] [Related]
20. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway.
Wu Y; Liu H; Weng H; Zhang X; Li P; Fan CL; Li B; Dong PL; Li L; Dooley S; Ding HG
Int J Oncol; 2015 Mar; 46(3):1275-85. PubMed ID: 25572615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
